ERBB2 and neoplasm: To further explore the clinical implications of the HER2–MARCKS interaction, we conducted additional RIME profiling using an HR-negative, HER2-positive tumor specimen (Case 3), which confirmed that MARCKS was consistently identified as a HER2 interactor even in the HR-negative context (Figure 5B).